NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis

Bio-Medicine.Org

LAWRENCE, Mass., Sept. 23, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM [1]), a leading manufacturer of innovative dialysis products, today commented on the just-released findings of an NIH sponsored study which shows that event rates, including mortality, were significantly higher for patients following the long (2-day) interdialytic interval associated with a three times per week dialysis schedule ("conventional dialysis"). The study entitled "Long Interdialytic Interval and Mortality among Patients Receiving Hemodialysis," compared the rates of death and cardiovascular-related hospital admissions on the day after the 2-day interdialytic interval with rates on other days for 32,065 in-center hemodialysis patients from the United States Renal Data System (USRDS) database.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

Today, the large majority of dialysis patients in the US receive conventional dialysis, which consists of treatment on a Monday/Wednesday/Friday or Tuesday/Thursday/Saturday schedule. This conventional in-center schedule leaves a 2-day gap between the last treatment of the preceding week and the first treatment of the following week, during which time toxins and fluids build up and stress the heart and body.

"This study's analysis that the conventional dialysis schedule may unnecessarily increase the risk of death for hundreds of thousands of dialysis patients adds to the clinical evidence that supports the benefits of a more frequent therapy paradigm. We believe the most cost effective place to do more frequent dialysis is in the patient's home with the NxStage System One," said Jeffrey H. Burbank, Chief Executive Officer, NxStage Medical Inc. "As we strive to improve the health and quality of life for dialysis patients with our life changing therapy, we look forward to working with policy makers to ens
'/>"/>

SOURCE [2]

Source URL (retrieved on *07/26/2014 - 10:28am*):
http://www.mdtmag.com/news/2011/09/nxstage-nih-study-published-new-england-journal-medicine-adds-growing-body-evidence-support-more-frequent-hemodialysis?qt-most_popular=0

Links:
[1] http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=NXTM
[2] http://www.bio-medicine.org/medicine-technology-1/NxStage-3A-NIH-Study-Published-in-New-England-Journal-of-Medicine-Adds-to-Growing-Body-of-Evidence-in-Support-of-More-Frequent-Hemodialysis-20491-1/